The incretin/glucagon system as a target for pharmacotherapy of obesity

S Del Prato, B Gallwitz, JJ Holst, JJ Meier - Obesity Reviews, 2022 - Wiley Online Library
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …
被引用次数：36 相关文章

The incretin/glucagon system as a target for pharmacotherapy of obesity

S Del Prato, B Gallwitz, JJ Holst, JJ Meier - OBESITY REVIEWS, 2022 - arpi.unipi.it
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …
[HTML] nih.gov

[HTML][HTML] The incretin/glucagon system as a target for pharmacotherapy of obesity

S Del Prato, B Gallwitz, JJ Holst, JJ Meier - Obesity Reviews, 2022 - ncbi.nlm.nih.gov
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …

[引用][C] The incretin/glucagon system as a target for pharmacotherapy of obesity

S Del Prato, B Gallwitz, JJ Holst, JJ Meier - Obesity Reviews, 2022 - ub01.uni-tuebingen.de
The incretin/glucagon system as a target for pharmacotherapy of obesity The incretin/glucagon
system as a target for pharmacotherapy of obesity DSpace Repositorium (Manakin basiert) …

The incretin/glucagon system as a target for pharmacotherapy of obesity.

S del Prato, B Gallwitz, JJ Holst, JJ Meier - 2021 - cabidigitallibrary.org
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …

The incretin/glucagon system as a target for pharmacotherapy of obesity

S Del Prato, B Gallwitz, JJ Holst… - Obesity reviews: an …, 2022 - pubmed.ncbi.nlm.nih.gov
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …

The incretin/glucagon system as a target for pharmacotherapy of obesity.

S Del Prato, B Gallwitz, JJ Holst… - Obesity Reviews: an …, 2021 - europepmc.org
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …
[PDF] sochob.cl

[PDF][PDF] The incretin/glucagon system as a target for pharmacotherapy of obesity

S Del Prato, B Gallwitz, JJ Holst, JJ Meier - 2021 - sochob.cl
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …

The incretin/glucagon system as a target for pharmacotherapy of obesity.

S Del Prato, B Gallwitz, JJ Holst, JJ Meier - Obesity Reviews, 2022 - search.ebscohost.com
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …

[引用][C] The incretin/glucagon system as a target for pharmacotherapy of obesity

S Del Prato, B Gallwitz, JJ Holst… - Obesity …, 2022 - tobias-lib.ub.uni-tuebingen.de
The incretin/glucagon system as a target for pharmacotherapy of obesity The incretin/glucagon
system as a target for pharmacotherapy of obesity DSpace Repositorium (Manakin basiert) …